Shares of NASDAQ:BLRX traded up $0.21 during midday trading on Thursday, reaching $1.45. 219,169 shares of the company’s stock were exchanged, compared to its average volume of 231,167. The stock has a market cap of $69.13 million, a price-to-earnings ratio of -2.59 and a beta of 2.04. The firm’s 50 day simple moving average is $1.44 and its two-hundred day simple moving average is $1.84. BioLineRx has a fifty-two week low of $1.01 and a fifty-two week high of $3.62.
BioLineRx (NASDAQ:BLRX – Get Rating) last announced its quarterly earnings data on Wednesday, March 16th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. On average, analysts expect that BioLineRx will post -0.51 EPS for the current year.
About BioLineRx (Get Rating)
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
- Get a free copy of the StockNews.com research report on BioLineRx (BLRX)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.